InvestorsHub Logo
Followers 4
Posts 1233
Boards Moderated 0
Alias Born 07/31/2014

Re: Headsupmonk post# 116843

Thursday, 10/01/2020 10:22:58 AM

Thursday, October 01, 2020 10:22:58 AM

Post# of 140474
I don’t believe this is the case. I still think that Enos is central to what they are doing. Single port is gonna be huge. He spoke about expansion into natural orifice, don’t think they would be talking this way if they were just an IP company. There is value in the IP and maybe they think couldn’t survive without harvesting some of that IP to allow them to finish development of Enos. Frederico and Schellhorn were there to get them a partnership with the right partner. Thus the relationship with Medtronic. Medtronic will eventually own Enos(IMO) - the VP of marketing is there. This would never be allowed in a million years if it wasn’t gonna end in a buyout. They would not rebrand themselves and allow their VP of marketing to go to any potential competitor just prior to rebrand. They are not rebranding the company, only the robot. I will be interested to see what Medtronics plans are for approaching this market. I think it would be a mistake to lead with a multiport in the US market. Most, if not all, academic hospitals in America are flush with the Davinci ecosystem. I suspect that they may approach Europe where they don’t have quite the stronghold with their multiport initially. They will spend next couple years building clinical case to expand Their multi port use in US. I think Single Port targeting ASCs in US and Endoluminal in GI will follow Europe and then in a couple years they will look to do the huge conversions by putting them all together to tackle the US Markets, all IMO.